<- Back To Blog

Catalyst Event｜September 2025 PDUFA Milestones to Watch

Celia
Celia ·
noah ai agent
PDUFA Event Overview – September 2025 (Expected)

In September 2025, the U.S. FDA will face several important PDUFA events, covering multiple therapeutic areas including SMA, transplant-associated thrombotic microangiopathy, acromegaly, Duchenne muscular dystrophy, and multiple sclerosis. The companies involved range from innovative biopharma firms such as Scholar Rock, Omeros, and Crinetics to multinational giants like Sanofi. The relevant pipelines include myostatin inhibitors, MASP-2 inhibitors, somatostatin receptor agonists, translational readthrough–inducing drugs, and BTK inhibitors.

Below, we dive into five key candidates, their mechanisms, clinical data, and potential to reshape patient care and investment opportunities.

1. Apitegromab: A New Era for SMA Treatment

  • What It Does: Apitegromab is a highly selective monoclonal antibody targeting myostatin, a protein that inhibits muscle growth. By blocking myostatin activation, it promotes skeletal muscle growth and strength.

  • Target Disease: Spinal Muscular Atrophy (SMA)

  • Clinical Highlights: In the Phase III SAPPHIRE trial, patients receiving Apitegromab (10 or 20 mg/kg) showed a statistically significant 1.8-point improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE) compared to placebo after 12 months (p=0.0192).

  • Approval Timeline: FDA’s PDUFA date is set for September 22, 2025, following priority review status granted in March 2025.

  • Impact on SMA Treatment: Apitegromab could shift SMA treatment from slowing disease progression to maximizing functional recovery. Unlike existing SMN-enhancing therapies (e.g., Nusinersen, Risdiplam), it addresses muscle damage directly, filling a critical gap.

  • Market Outlook: If approved, expect U.S. commercialization in Q4 2025, with sales data and long-term ONYX study results driving investor interest.

2. Narsoplimab: First-in-Class Hope for TA-TMA

  • What It Does: Narsoplimab, a monoclonal antibody, targets MASP-2 to block the complement system’s lectin pathway, a key driver of transplant-associated thrombotic microangiopathy (TA-TMA). It preserves the classical pathway which is critical for adaptive immunity, maintaining infection-fighting immunity.

  • Target Disease: TA-TMA, a severe complication of hematopoietic stem cell transplantation.

  • Clinical Highlights: A pivotal single-arm trial showed Narsoplimab reduced mortality risk by over three times compared to an external control group.

  • Approval Timeline: FDA review began in May 2025, with a target approval date in late September 2025, after a prior rejection in 2021 due to insufficient control data.

  • Impact on SMA Treatment: If approved, Narsoplimab will be the first therapy specifically for TA-TMA, addressing a major unmet need.

  • Market Outlook: Its first-mover advantage could lead to rapid adoption, with commercialization progress closely watched.

3. Paltusotine: Oral Breakthrough for Acromegaly

  • What It Does: Paltusotine is a novel oral small-molecule SST2 agonist that mimics somatostatin to normalize growth hormone (GH) and IGF-1 levels.

  • Target Disease: Acromegaly

  • Clinical Highlights: The Phase III PATHFNDR-1 trial showed most patients maintained stable biochemical control after switching to Paltusotine, while PATHFNDR-2 confirmed superior efficacy over placebo in treatment-first or second-line patients. Notably, 88.9% of patients preferred oral Paltusotine over injectable therapies.

  • Approval Timeline: FDA accepted the NDA in December 2024, with a PDUFA date of September 25, 2025.

  • Impact on SMA Treatment: As the first once-daily oral SST2 agonist, Paltusotine eliminates the burden of injections, offering a patient-friendly alternative with strong clinical backing.

  • Market Outlook: High patient preference and robust data position it for rapid market uptake post-approval.

4. Tolebrutinib: A Game-Changer for nrSPMS

  • What It Does: Tolebrutinib is a selective, CNS-penetrant BTK inhibitor with dual action: it suppresses peripheral B-cell activation and, crucially, crosses the blood-brain barrier to inhibit microglia-driven inflammation in the CNS.

  • Target Disease: on-relapsing secondary progressive multiple sclerosis (nrSPMS) and relapsing MS (RMS)

  • Clinical Highlights: The Phase III HERCULES trial showed a 31% reduction in 6-month confirmed disability progression (HR=0.69, p=0.003), with nearly double the disability improvement rate (10% vs. 5%) compared to placebo. While GEMINI 1 & 2 trials missed the primary endpoint for relapse rate, pooled analysis showed a 29% reduction in disability worsening.

  • Approval Timeline: FDA accepted the NDA for nrSPMS in March 2025, with a PDUFA date of September 28, 2025.

  • Impact on SMA Treatment: Tolebrutinib’s ability to target progressive MS, an area with limited options, makes it a standout. Its CNS penetration sets it apart from competitors like Roche’s Fenebrutinib and Novartis’ Remibrutinib.

  • Market Outlook: Analysts predict peak sales of $2–3.5 billion, driven by its potential in nrSPMS and upcoming PPMS data from the PERSEUS trial.

5. Translarna: Oral Hope for Nonsense Mutation DMD

  • What It Does: Translarna (ataluren) is an oral small-molecule drug that promotes read-through of nonsense mutations in Duchenne muscular dystrophy (DMD), enabling functional protein production with low toxicity.

  • Target Disease: Nonsense mutation DMD (nmDMD)

  • Clinical Highlights:The Phase III Study 041 showed a 14.4-meter improvement in 6-minute walk distance (p=0.0248), with a 42.9-meter gain in patients with baseline 300–400 meters (p=0.007). Long-term STRIDE data delayed loss of ambulation by 3.5 years.

  • Approval Timeline: FDA accepted the resubmitted NDA in March 2024, with a decision expected in September 2025, following a 2017 rejection.

  • Impact on SMA Treatment: If approved, Translarna would be the first oral therapy for nmDMD in the U.S., offering a safer alternative to earlier read-through drugs, e.g. Gentamicin.

  • Market Outlook: Its approval could pave the way for next-generation read-through therapies and combination strategies.